R-Pharm: all 78 studies

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean FeverNot yet recruitingNCT07880886Phase 3
• Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's DiseaseNot yet recruitingNCT07625384Phase 3
• A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRIRecruitingNCT07543744Phase 1
• Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic ArthritisRecruitingNCT07517575Phase 2
• Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung DiseasesRecruitingNCT06440746Phase 2/3
• Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean FeverRecruitingNCT05190991Phase 2
• Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial InfarctionCompletedNCT04463251Phase 2Results posted
• Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)CompletedNCT04380519Phase 2/3Results posted
• Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4CompletedNCT04246762Phase 1Results posted
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout AttackTerminatedNCT04067492Phase 2Results posted
• Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.CompletedNCT03575702Phase 3Results posted
• Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired PneumoniaCompletedNCT03551210Phase 3Results posted
• A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral DrugsCompletedNCT03537404Phase 1Results posted
• Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid ArthritisCompletedNCT03120949Phase 3Results posted
• Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active DiseaseCompletedNCT02760433Phase 3Results posted
• Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active DiseaseCompletedNCT02760407Phase 3Results posted
• Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active DiseaseCompletedNCT02760368Phase 3Results posted
• Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy SubjectsCompletedNCT02667639Phase 1Results posted
• Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial HypertensionCompletedNCT02248961Phase 3Results posted
• Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric CancerCompletedNCT00983801Phase 2Results posted
• A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial CancerTerminatedNCT00883116Phase 3Results posted
• Phase I Combination Ixabepilone + CisplatinCompletedNCT00832117Phase 1Results posted
• A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung CancerCompletedNCT00723957Phase 2Results posted
• Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung CancerCompletedNCT00683904Phase 1Results posted
• Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerTerminatedNCT00634088Phase 1Results posted
• Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast CancerCompletedNCT00633464Phase 2Results posted
• Phase 1 Trial of Oral IxabepiloneTerminatedNCT00632424Phase 1Results posted
• Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast CancerCompletedNCT00593827Phase 2Results posted
• A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast CancerCompletedNCT00568022Phase 1Results posted
• Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast CancerTerminatedNCT00546364Phase 2Results posted
• A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast CancerCompletedNCT00490646Phase 2Results posted
• A Phase I Study of Oral Ixabepilone in Subjects With Advanced CancerCompletedNCT00422097Phase 1Results posted
• A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic CancerCompletedNCT00383149Phase 2Results posted
• A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast CancerCompletedNCT00370552Phase 2Results posted
• Phase I Combination w/ EpirubicinCompletedNCT00322374Phase 1Results posted
• Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced CancerCompletedNCT00207090Phase 1Results posted
• Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.CompletedNCT00162136Phase 1Results posted
• Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast CancerCompletedNCT00082433Phase 3Results posted
• Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast CancerCompletedNCT00080301Phase 3Results posted
• Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE)Active, not recruitingNCT07670546Phase 3
• A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With ExacerbationsActive, not recruitingNCT07597668Phase 1
• A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate CancerActive, not recruitingNCT07553988Phase 2
• A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell CarcinomaCompletedNCT07435324Phase 3
• A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell CarcinomaCompletedNCT07435311Phase 1
• A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast CancerActive, not recruitingNCT07386938Phase 3
• Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy VolunteersCompletedNCT07206043Phase 1
• Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin MelanomaCompletedNCT06320353Phase 3
• Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant NeoplasmsCompletedNCT06307093Phase 1
• Efficacy and Safety Evaluation of Refralon®, Concentrate for Solution for Intravenous Injection in Patients With Paroxysmal and Persistent Atrial Fibrillation and FlutterCompletedNCT05773170
• Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent PericarditisActive, not recruitingNCT05673902Phase 3
• Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)WithdrawnNCT05432960Phase 3
• Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) InfectionCompletedNCT05196477
• Study of Efficacy of Different Treatment Regimens of OlokizumabStatus unknownNCT05187793Phase 3
• Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent PericarditisSuspendedNCT05107934Phase 2/3
• Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of ColchicineActive, not recruitingNCT05092776Phase 2
• Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)CompletedNCT04760730Phase 1/2
• Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent PericarditisCompletedNCT04692766Phase 2/3
• Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 PreventionCompletedNCT04686773Phase 2
• Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19CompletedNCT04684446Phase 1/2
• Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19CompletedNCT04501783Phase 3
• Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).WithdrawnNCT04452474Phase 2/3
• Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1CompletedNCT04246723Phase 2
• Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler SyndromeWithdrawnNCT04213274Phase 2
• Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)CompletedNCT03833362Phase 3
• A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched VolunteersCompletedNCT03832426Phase 1
• Comparative Clinical Study of Efficacy and Safety of Remimazolam and Propofol in Patients Undergoing Elective Surgery Under General AnaesthesiaCompletedNCT03669484Phase 3
• Efficacy and Safety Evaluating Study of Odelepran for the Use in Patient With Alcohol DependenceCompletedNCT03663374Phase 3
• Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin®CompletedNCT03659305Phase 1
• Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1bCompletedNCT03485846Phase 2
• A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An AnthracyclineCompletedNCT01027208Phase 2
• Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane ResistantCompletedNCT01019577Phase 2
• Study of Ixabepilone (BMS-247550) in Patients With Solid TumorsCompletedNCT01018966Phase 1
• Ixabepilone Administered as an Enteric Coated Formulation.CompletedNCT00309049Phase 1/2
• Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced MalignanciesCompletedNCT00207129Phase 1
• Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)CompletedNCT00080262Phase 2
• BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast CancerStatus unknownNCT00049244Phase 1
• A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based ChemotherapyCompletedNCT00035516Phase 2
• BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous TherapyCompletedNCT00004927Phase 1

← R-Pharm overview and focus areas